CJC-1295 No DAC + Ipamorelin Growth Hormone Pulse Stack Protocol

CJC-1295 No DAC + Ipamorelin Growth Hormone Pulse Stack Quick Reference Dosing Card

What Is the CJC-1295 No DAC + Ipamorelin Growth Hormone Pulse Stack?

The CJC-1295 No DAC + Ipamorelin stack is the most popular two-peptide combination used to support your body's own growth hormone (GH) production. Rather than injecting synthetic growth hormone directly, this stack signals your pituitary gland, the small gland at the base of your brain that controls GH release, to produce stronger natural GH pulses.

It works by targeting two different signaling pathways at once. CJC-1295 No DAC (also called Mod GRF 1-29) is a GHRH analog, meaning it mimics one of the hormones your body already uses to trigger GH release. Ipamorelin works through a separate pathway called the ghrelin receptor (GHS-R1a), adding a second GH signal on top of the first. Think of it like pressing two different "release GH" buttons at the same time instead of just one.

This stack is commonly explored in research settings focused on sleep quality, recovery, and body composition. It uses the "No DAC" version of CJC-1295 specifically because it clears the body quickly (~30 minutes), which preserves the natural pulse pattern of GH release rather than keeping levels elevated for days. That's why it's called a GH pulse stack. It's designed around short, strong bursts rather than sustained elevation.

No randomized clinical trial has evaluated this exact two-compound stack as a combination protocol. Current use is based on individual compound data, mechanism-level synergy, and long-running community protocol conventions.

How the Growth Hormone Pulse Stack Works: Dual-Receptor Growth Hormone Pulse Amplification

Pathway 1: Two Signals Are Stronger Than One (GHRH-R + GHS-R1a Dual Activation)

Your body has two main "switches" that trigger growth hormone release. CJC-1295 No DAC flips the first switch — called the GHRH receptor — which tells the GH-producing cells in your pituitary gland to start releasing growth hormone. Ipamorelin flips a completely different switch — the ghrelin receptor (GHS-R1a) — which adds a second release signal through a separate pathway. Because these two switches don't interfere with each other, activating both at the same time produces a stronger GH pulse than either one alone.

Pathway 2: Opening a Wider Window for GH Pulses (Somatostatin Counterbalance)

Your body also has a natural "brake" on GH release called somatostatin. GHRH signaling from CJC-1295 No DAC can ease this brake, while Ipamorelin pushes GH release from the ghrelin side. Together, they create a wider window for GH pulses — especially when you're in a fasted state (at least 1–2 hours after eating), because insulin also acts as a GH brake.

Pathway 3: Short-Acting Design That Supports Natural Pulse Patterns

This stack uses CJC No DAC (not the DAC version) on purpose. The No DAC form clears the body in about 30 minutes, which means each injection produces a discrete GH pulse rather than keeping levels elevated for days. This also makes dose adjustments faster — if you lower your dose, the change takes effect within hours, not days.

Pathway 4: Cleaner Hormonal Profile Than Older Alternatives

Older GH-releasing peptides (like GHRP-6 and GHRP-2) often triggered unwanted increases in cortisol (a stress hormone) and prolactin. Ipamorelin is far more selective — it stimulates GH release through the ghrelin receptor without those hormonal side effects, which is why it's the preferred pairing for CJC No DAC in protocols focused on GH pulse support with minimal hormonal noise.

CJC-1295 No DAC + Ipamorelin Dosing Protocol & Schedule

The table below shows a typical CJC-1295 No DAC + Ipamorelin dosing protocol broken into phases. Start at the top and work down — most users begin with the Initiation phase and progress over several weeks. The "Split Protocol" phase is optional and only used when a second daily dose is desired.

Dosing Notes

1. Most protocols keep both compounds in a 1:1 or near-1:1 microgram range, with Ipamorelin sometimes slightly higher.
2. Fasted administration is standard: at least 1-2 hours after the last meal, and delay food for about 20-30 minutes post-injection.
3. Bedtime timing is prioritized to align with natural nocturnal GH pulses.
4. If a dose is missed, resume the next scheduled dose; do not double up.

CJC-1295 No DAC + Ipamorelin Reconstitution Guide

Market Blend Snapshot (Web Research - March 6, 2026)

1. The most common listed premix is 5 mg CJC-1295 No DAC + 5 mg Ipamorelin (10 mg total, 1:1 ratio).
2. Multiple suppliers explicitly label this as a fixed-ratio convenience blend.
3. Non-1:1 blends also exist in the market (for example 12 mg/6 mg), reinforcing the need to verify each vial's component ratio before dose math.

This is market-availability data, not clinical efficacy evidence.

Step-by-Step Reconstitution

1. Gather peptide vial(s), BAC water, alcohol swabs, and U-100 insulin syringes.
2. Swab vial tops and let dry.
3. Draw BAC water volume.
4. Inject BAC water slowly down vial wall (do not blast powder directly).
5. Gently swirl/roll until clear; do not shake aggressively.
6. Label vial with reconstitution date and concentration.
7. Refrigerate immediately at 2-8 C.

CJC-1295 No DAC + Ipamorelin Side Effects - Combined Safety Considerations

Most common side effects reported in practice patterns

• Injection site redness, itching, or mild swelling
• Transient flushing or warmth
• Mild headache
• Water retention or bloating
• Sleep architecture changes (sometimes improved deep sleep, sometimes vivid dreams)

Dose-dependent behavior

Side effects generally increase with higher per-injection doses and higher daily frequency. Running conservative bedtime-only dosing first reduces early intolerance.

Additive stack considerations

1. Both compounds push GH/IGF-1 pathways, so edema and insulin-sensitivity concerns can be more noticeable than with either peptide alone.
2. Appetite effects are typically mild with Ipamorelin versus older GHRPs, but individual response varies.
3. Because this stack is short-acting, adverse effects usually resolve faster than long-acting DAC-based protocols once dosing is reduced or paused.

Contraindication and caution profile (mechanism-based)

• Active malignancy or high cancer-risk context
• Uncontrolled diabetes or significant insulin resistance
• Significant cardiovascular disease
• Pregnancy or breastfeeding
• Known hypersensitivity to peptide excipients

Quality-control risk remains a primary safety issue: concentration errors, contamination, or degraded product quality from non-verified suppliers can create more risk than the peptide mechanism itself.

For combined side effect considerations when stacking, see the PepPal Side Effects Guide.

Research Evidence for the CJC-1295 No DAC + Ipamorelin Stack

There are currently no randomized controlled trials testing CJC-1295 No DAC + Ipamorelin as a combined stack protocol for performance, anti-aging, body composition, or recovery endpoints.

As of March 6, 2026, ClinicalTrials.gov lists studies for CJC-family compounds and for Ipamorelin individually, but no registered study was found testing this exact two-peptide combination together. The table below shows what evidence *does* exist, ranked from strongest (direct combination data) to weakest (community reports):

Practical Interpretation

1. Stack popularity is driven more by mechanistic complementarity and market use than direct outcomes trials.
2. Human evidence for each ingredient exists, and older GHRH+GHRP studies support pathway-level synergy, but direct CJC No DAC + Ipamorelin outcomes remain inferential.
3. Early stack-specific signals are preclinical; clinical-grade claims should be avoided until direct human combination trials are available.

Storage & Handling - CJC-1295 No DAC and Ipamorelin

Handling standards

1. Always use bacteriostatic water for multi-dose vials.
2. Use sterile single-use syringes and alcohol prep.
3. Do not shake reconstituted vials.
4. Discard if solution is cloudy, discolored, or contains persistent particulates.
5. Use sharps disposal for all used needles and syringes.

CJC-1295 No DAC + Ipamorelin vs Single-Agent and DAC-Based Options

The table below compares the CJC-1295 No DAC + Ipamorelin GH pulse stack against using either peptide alone and against the longer-acting DAC-based alternative. Look at the "Best use-case fit" row to see which option matches your research goals:

Comparison summary: for protocols that specifically want physiologic pulse-style signaling and rapid dose adjustability, CJC No DAC + Ipamorelin remains the preferred stack architecture over DAC-based combinations.

Related Stacking Protocols

1. CJC-1295 No DAC + Ipamorelin + IGF-1 LR3 (Muscle/Recomp Stack): Compounds: CJC-1295 No DAC (100-150 mcg) + Ipamorelin (100-200 mcg) + IGF-1 LR3 (20-50 mcg). Rationale: adds a direct muscle-growth signal (IGF-1 LR3) on top of GH pulse support for more aggressive body-recomposition research.
2. Wolverine Stack + GH Pulse Layer: Compounds: BPC-157 + TB-500 + CJC-1295 No DAC/Ipamorelin (bedtime). Rationale: uses the bedtime GH pulse to boost recovery alongside the Wolverine Stack's tissue-repair peptides. Wolverine Stack
3. GLOW Stack + GH Pulse Layer: Compounds: BPC-157 + TB-500 + GHK-Cu + CJC-1295 No DAC/Ipamorelin. Rationale: adds GH pulse support to a skin and tissue repair stack, potentially enhancing collagen production and recovery. GLOW Stack
4. Retatrutide + CJC-1295 No DAC/Ipamorelin (Advanced Recomp): Compounds: Retatrutide + bedtime CJC/Ipamorelin pulse. Rationale: pairs a fat-loss and appetite compound (Retatrutide) with bedtime GH pulse support for advanced body-composition protocols.

COA-Verified Suppliers Carrying CJC-1295 No DAC and Ipamorelin

1. Orbitrex Peptides - COA-verified supplier carrying CJC-1295 No DAC and Ipamorelin in separate and stack formats. Visit Site -> | Code: PEPPAL
2. Paradigm Peptides - Published batch COAs with U.S.-based fulfillment and common GH stack inventory. Visit Site -> | Code: PEPPAL
3. Pivot Labs - Research-grade peptide catalog with lot-level testing documentation. Visit Site -> | Code: PEPPAL
4. Peptide Tech - Supplier with third-party purity reporting and frequent stack bundle availability. Visit Site -> | Code: PEPPAL

Frequently Asked Questions - CJC-1295 No DAC + Ipamorelin Growth Hormone Pulse Stack

Sources & Research

1. Teichman SL, Neale A, Lawrence B, et al. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." Journal of Clinical Endocrinology & Metabolism, 2006 Link.
2. Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone Persists during Continuous Stimulation by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006 Link.
3. Jette L, Leger R, Thibaudeau K, et al. "Identification of CJC-1295 as a Long-Lasting GRF Analog." Endocrinology, 2005 Link.
4. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers." Pharmaceutical Research, 1999 Link.
5. Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the First Selective Growth Hormone Secretagogue." European Journal of Endocrinology, 1998 Link.
6. Beck DE, Sweeney WB, McCarter MD. "Ipamorelin for Postoperative Ileus in Bowel Resection Patients." International Journal of Colorectal Disease, 2014 Link.
7. Mayfield CK, Bolia IK, Feingold CL, et al. "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." American Journal of Sports Medicine, 2026 Link.
8. Micic D, Popovic V, Kendereski A, et al. "Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood." Clinical Endocrinology, 1995 Link.
9. Villas-Boas Weffort RF, Ramos-Dias JC, Chipoch C, Lengyel AM. "Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus." Metabolism, 1997 Link.
10. Ishida J, Saitoh M, Ebner N, et al. "Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development." JCSM Rapid Communications, 2020 Link.
11. ClinicalTrials.gov "Ipamorelin in Postoperative Ileus." Identifier: NCT00672074. Clinical Trial Registry, n.d. Link.
12. ClinicalTrials.gov "Safety and Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function." Identifier: NCT01280344. Clinical Trial Registry, n.d. Link.
13. ClinicalTrials.gov "A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity." Identifier: NCT00267527. Clinical Trial Registry, n.d. Link.
14. FDA "Tailor Made Compounding LLC - 594743 - 04/01/2020." Warning Letter, 2020 Link.
15. FDA "Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of All Sterile Compounded Drug Products Due to A Lack of Sterility Assurance." Recall Notice, n.d. Link.
16. BlueWell Peptides "CJC-1295 No DAC + Ipamorelin 10mg Blend (5mg/5mg)." Market Listing, 2026 Link.
17. Blue Sky Peptide "Blend CJC 1295 NO DAC 5MG with Ipamorelin 5MG." Market Listing, 2026 Link.
18. Limitless Life Nootropics "CJC-1295 + Ipamorelin Blend (12mg Ipamorelin / 6mg CJC-1295 No DAC)." Market Listing, 2026 Link.

Related Protocols

Disclaimer